Thursday’s closing bell saw the Dow Jones index logging a modest gain of approximately 50 points. Share transactions by corporate insiders often serve as a barometer of their confidence or apprehension concerning a company’s future. Investors and traders eyeing penny stocks may find these dealings a noteworthy factor in their investment or trading considerations.
Below, we take a glimpse at a handful of recent notable insider transactions within the domain of penny stocks. For a more extensive catalog, delve into Benzinga’s insider transactions platform.
Inside Scoop at Dalrada Financial
- The Deal: Dalrada Financial Corporation DFCO Chief Executive Officer Brian Bonar acquired a total of 52,600 shares at an average price of $0.22. The acquisition amounted to approximately $11,831.
- What’s Afoot: The company’s stock witnessed a drop of around 16% over the past month.
- About Dalrada Financial: Dalrada Financial Corp, headquartered in the United States, provides financial, insurance, benefit, and business process outsourcing products and services to companies.
An Eye on Research Frontiers
- The Trade: Research Frontiers Incorporated REFR Director Darryl Daigle bought a total of 1,000 shares at an average price of $1.00, incurring an expense of around $1,000.
- Current Developments: On Nov. 2, Research Frontiers reported a narrower third-quarter loss.
- About Research Frontiers: Research Frontiers Inc delves into the development and marketing of technology and devices for light-flow control.
For a more comprehensive update, delve into our coverage of Investor Sentiment Edges Higher As S&P 500 Briefly Breaches 5,000 Level
A Deeper Look at DBV Technologies
- The Purchase: DBV Technologies S.A. DBVT Director Adora Ndu snatched a total of 1,825 shares at an average price of $0.89, entailing an expenditure of around $1,624.
- Recent Events: DBV Technologies unveiled the 2-year results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin™ peanut in toddlers on Nov. 10.
- About DBV Technologies: DBV Technologies SA is a clinical-stage specialized biopharmaceutical company striving to revolutionize immunotherapy through the development of a new technology platform called Viaskin.
Don’t miss our premarket coverage
